In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-13 of 13 for your search:
Drug:  peginterferon alfa-2b
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: MCL2004-1, NCT00209209
2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: daliah2011, NCT01387763
3.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: EORTC-18081, 2009-010273-20, NCT01502696
4.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CML V, 2010-024262-22, NCT01657604
5.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PITCH trial, NCT01637532
6.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CHIP trial, 2010-023124-24, NCT01639885
7.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 months to 21 years
Sponsor: NCI, Other
Protocol IDs: UPCI 06-116, NCT00396019
8.

Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: NCI
Protocol IDs: 080130, 08-C-0130, NCI-08-C-0130, NCI-P06096, NCT00678951
9.

Phase: Phase II
Type: Treatment
Status: Active
Age: 2 to 30
Sponsor: Other
Protocol IDs: 2008-260, NCT00846430
10.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: NordCML007, 2011-005989-38, NCT01725204
11.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000581060, OSU-06113, OSU-2007C0088, NCT00589550
12.

Phase: Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: MCC-16755, NCT01496807
13.

Phase: Phase I
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: P08556, MK-4031-370, NCT01636960
New Search